Gene Therapeutics & RNAi Nucleic Acid Pharma

PUBLISHER: 360iResearch | PRODUCT CODE: 2173048

PUBLISHER: 360iResearch | PRODUCT CODE: 2173048

siRNA Therapeutics Market - Global Forecast 2026-2032

PUBLISHED: November 5, 2026

PAGES: 182 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The siRNA Therapeutics Market is projected to grow by USD 6.61 billion at a CAGR of 10.68% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 3.25 billion
Estimated Year [2026]	USD 3.58 billion
Forecast Year [2032]	USD 6.61 billion
CAGR (%)	10.68%

siRNA Therapeutics: Executive Overview

Small interfering RNA (siRNA) therapeutics are medicines designed to selectively silence specific genes by directing cellular machinery to degrade complementary messenger RNA. Their clinical value rests on high target specificity, the ability to address previously difficult protein targets, and the potential for infrequent dosing when delivery systems support durable activity. The field is advancing through improvements in sequence design, chemical stabilization, conjugation, and tissue-directed delivery.

Delivery, Durability, and Translational Progress Are Reshaping the Field

The landscape is shifting from proof of gene silencing toward reliable delivery to clinically relevant tissues. Ligand conjugates, lipid-based systems, and other delivery approaches are being refined to improve uptake, reduce off-target effects, and extend pharmacologic activity. Progress is also being shaped by biomarker-guided development, clearer dose-response characterization, and increasing attention to manufacturing consistency, long-term safety, immune effects, and treatment access.

Artificial Intelligence Accelerates Design, Prioritization, and Development

Artificial intelligence is contributing to siRNA discovery by supporting target identification, sequence optimization, off-target prediction, delivery-material selection, and analysis of transcriptomic and clinical datasets. Its cumulative impact depends on the quality and diversity of training data, experimental validation, and transparent model governance. AI can shorten iteration cycles and improve candidate prioritization, but it does not replace laboratory confirmation, toxicology, regulatory review, or post-treatment monitoring.

Regional Insights: Delivery Capability and Regulatory Readiness Shape Adoption

North America benefits from established biotechnology infrastructure, clinical research capacity, and substantial experience with advanced therapeutics. Europe combines strong academic translational networks with coordinated regulatory and health-technology assessment considerations. Asia-Pacific is supported by expanding biopharmaceutical capabilities and significant research activity, while regional differences in reimbursement and clinical infrastructure remain important. Latin America is developing specialized research and treatment capacity, with access and supply-chain reliability continuing to influence implementation. The Middle East is strengthening precision-medicine and innovation ecosystems, whereas Africa requires sustained investment in clinical networks, diagnostics, cold-chain logistics, and equitable access.

Group Insights: Cooperation and Policy Alignment Influence Scale

ASEAN markets present varied regulatory systems, healthcare capacity, and access conditions, making regional cooperation especially relevant. BRICS members combine large scientific and patient populations with diverse development and reimbursement environments. The European Union offers regulatory coordination alongside country-level differences in health technology assessment and procurement. G7 countries contribute advanced research, manufacturing, and financing capabilities. GCC states are investing in healthcare modernization and precision medicine, while NATO members provide broad research and industrial networks; these groupings are not uniform markets, so implementation strategies must account for national policy and infrastructure differences.

Country Insights: National Strengths Create Different Development Pathways

The United States and Canada combine strong research systems with experienced clinical-development environments. The United Kingdom, Germany, France, Italy, and Spain offer established academic and healthcare networks, while differences in assessment, procurement, and reimbursement affect uptake. China, Japan, South Korea, India, and Australia are strengthening research, manufacturing, and translational capabilities through distinct regulatory and healthcare frameworks. Brazil and Mexico are important Latin American centers for clinical activity and healthcare delivery, with access shaped by institutional capacity and supply chains. Russia maintains scientific and clinical capabilities, although collaboration, procurement, and regulatory conditions require careful assessment.

Strategic Priorities for Leaders in siRNA Therapeutics

Industry leaders should prioritize delivery platforms matched to tissue biology, incorporate off-target and immune-risk testing early, and use clinically meaningful biomarkers to demonstrate durable response. Development plans should integrate manufacturing controls, scalable analytical methods, and clear long-term follow-up. Partnerships with hospitals, diagnostic providers, regulators, and patient organizations can improve trial execution and access planning. AI should be deployed with validated datasets, human oversight, reproducible workflows, and explicit controls for bias, privacy, and model drift. Regional launch strategies should reflect local reimbursement, infrastructure, and treatment-monitoring requirements rather than assuming a uniform global pathway.

Research Methodology: Evidence-Based Assessment of the siRNA Therapeutics Landscape

This executive summary uses a structured synthesis of publicly available scientific literature, clinical-trial records, regulatory documents, health-system information, and authoritative policy and technology sources. Evidence was assessed qualitatively for relevance, recency, methodological strength, and geographic applicability. Findings were organized around therapeutic mechanisms, delivery technologies, development practices, artificial-intelligence applications, and regional, group, and country conditions. No market estimates, market sizing, market shares, or forecasts are presented.

Conclusion: Precision Delivery and Evidence Discipline Will Define Progress

siRNA therapeutics are moving toward a more mature model in which selective gene silencing must be paired with dependable tissue delivery, durable benefit, manageable safety, and practical treatment access. Scientific progress is being reinforced by improved analytics and AI-enabled prioritization, but success remains dependent on experimental validation and robust clinical evidence. Organizations that align platform innovation with manufacturing discipline, regulatory engagement, health-system realities, and patient needs will be best positioned to translate gene-silencing science into durable clinical value.

Product Code: MRR-FA284DCDE1BC

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. siRNA Therapeutics Market, by Drug Agent

7.1. Introduction
7.2. Givosiran
7.3. Inclisiran
7.4. Lumasiran
7.5. Nedosiran
7.6. Patisiran
7.7. Vutrisiran

8. siRNA Therapeutics Market, by Delivery Systems

8.1. Introduction
8.2. Lipid Nanoparticles
8.3. Peptide Delivery Systems
8.4. Polymer Conjugates

9. siRNA Therapeutics Market, by Route of Administration

9.1. Introduction
9.2. Intravenous (IV)
9.3. Subcutaneous

10. siRNA Therapeutics Market, by Therapeutic Categories

10.1. Introduction
10.2. Cardiovascular Disorders
10.3. Immunological Disorders
10.4. Infectious Diseases
- 10.4.1. Bacterial Infections
- 10.4.2. Viral Infections
10.5. Metabolic Disorders
10.6. Neurological Disorders
- 10.6.1. Alzheimer's Disease
- 10.6.2. Parkinson's Disease
10.7. Oncology
- 10.7.1. Hematologic Malignancies
  - 10.7.1.1. Leukemia
  - 10.7.1.2. Lymphoma
- 10.7.2. Solid Tumors
  - 10.7.2.1. Breast Cancer
  - 10.7.2.2. Lung Cancer
  - 10.7.2.3. Prostate Cancer

11. siRNA Therapeutics Market, by End-User

11.1. Introduction
11.2. Contract Research Organizations
11.3. Hospitals & Clinics
11.4. Pharmaceutical Companies
11.5. Research & Academic Institutes

12. siRNA Therapeutics Market, by Region

12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa

13. siRNA Therapeutics Market, by Group

13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO

14. siRNA Therapeutics Market, by Country

14.1. Introduction
14.2. United States
14.3. Germany
14.4. China
14.5. United Kingdom
14.6. India
14.7. Japan
14.8. Russia
14.9. Brazil
14.10. Canada
14.11. Italy
14.12. Mexico
14.13. France
14.14. Spain
14.15. Australia
14.16. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
- 15.2.1. Concentration Ratio (CR)
- 15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Alnylam Pharmaceuticals Inc.
16.2. Alys Pharmaceuticals Inc.
16.3. Arbutus Biopharma Corporation
16.4. Arcturus Therapeutics, Inc. by Alcobra Ltd.
16.5. Aro Biotherapeutics Co.
16.6. Arrowhead Pharmaceuticals Inc.
16.7. Atalanta Therapeutics
16.8. Biocon Ltd.
16.9. e-Therapeutics Plc
16.10. Eli Lilly and Company
16.11. Ionis Pharmaceuticals Inc.
16.12. Merck & Co. Inc.
16.13. Moderna Therapeutics
16.14. Novartis AG
16.15. Novo Nordisk A/S
16.16. Phio Pharmaceuticals, Inc.
16.17. Quark Pharmaceuticals inc.
16.18. Risen Pharma Tech Co Ltd
16.19. Roche Holding AG
16.20. Shanghai Argo Biopharmaceutical Co., Ltd.
16.21. Silence Therapeutics plc
16.22. Sirius Therapeutics Inc.
16.23. Sirnaomics Inc.
16.24. Suzhou Sanegene Bio Inc.
16.25. Synerk Inc.
16.26. Thermo Fisher Scientific Inc.
16.27. Vir Biotechnology, Inc.
16.28. Wave Life Sciences USA, Inc.

17. Key Experts